Medexus Pharmaceuticals Statistics
Total Valuation
MEDXF has a market cap or net worth of 65.71 million. The enterprise value is 77.61 million.
| Market Cap | 65.71M |
| Enterprise Value | 77.61M |
Important Dates
The next estimated earnings date is Wednesday, February 11, 2026.
| Earnings Date | Feb 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 32.45M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +22.26% |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | 8.06% |
| Owned by Institutions (%) | 3.36% |
| Float | 29.83M |
Valuation Ratios
The trailing PE ratio is 172.47.
| PE Ratio | 172.47 |
| Forward PE | n/a |
| PS Ratio | 0.63 |
| PB Ratio | 1.25 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 4.11 |
| P/OCF Ratio | 4.05 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.07, with an EV/FCF ratio of 4.85.
| EV / Earnings | 203.71 |
| EV / Sales | 0.73 |
| EV / EBITDA | 5.07 |
| EV / EBIT | 12.71 |
| EV / FCF | 4.85 |
Financial Position
The company has a current ratio of 0.83, with a Debt / Equity ratio of 0.40.
| Current Ratio | 0.83 |
| Quick Ratio | 0.29 |
| Debt / Equity | 0.40 |
| Debt / EBITDA | 1.40 |
| Debt / FCF | 1.32 |
| Interest Coverage | 0.88 |
Financial Efficiency
Return on equity (ROE) is 0.89% and return on invested capital (ROIC) is 5.02%.
| Return on Equity (ROE) | 0.89% |
| Return on Assets (ROA) | 2.54% |
| Return on Invested Capital (ROIC) | 5.02% |
| Return on Capital Employed (ROCE) | 8.05% |
| Revenue Per Employee | 1.14M |
| Profits Per Employee | 4,187 |
| Employee Count | 91 |
| Asset Turnover | 0.71 |
| Inventory Turnover | 1.11 |
Taxes
In the past 12 months, MEDXF has paid 28,000 in taxes.
| Income Tax | 28,000 |
| Effective Tax Rate | 6.85% |
Stock Price Statistics
The stock price has decreased by -9.82% in the last 52 weeks. The beta is 1.90, so MEDXF's price volatility has been higher than the market average.
| Beta (5Y) | 1.90 |
| 52-Week Price Change | -9.82% |
| 50-Day Moving Average | 1.94 |
| 200-Day Moving Average | 1.99 |
| Relative Strength Index (RSI) | 59.36 |
| Average Volume (20 Days) | 16,789 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MEDXF had revenue of 104.10 million and earned 381,000 in profits. Earnings per share was 0.01.
| Revenue | 104.10M |
| Gross Profit | 63.95M |
| Operating Income | 5.99M |
| Pretax Income | 409,000 |
| Net Income | 381,000 |
| EBITDA | 14.88M |
| EBIT | 5.99M |
| Earnings Per Share (EPS) | 0.01 |
Balance Sheet
The company has 9.38 million in cash and 21.07 million in debt, giving a net cash position of -11.69 million.
| Cash & Cash Equivalents | 9.38M |
| Total Debt | 21.07M |
| Net Cash | -11.69M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 52.42M |
| Book Value Per Share | 1.62 |
| Working Capital | -12.51M |
Cash Flow
In the last 12 months, operating cash flow was 16.24 million and capital expenditures -246,000, giving a free cash flow of 16.00 million.
| Operating Cash Flow | 16.24M |
| Capital Expenditures | -246,000 |
| Free Cash Flow | 16.00M |
| FCF Per Share | n/a |
Margins
Gross margin is 61.43%, with operating and profit margins of 5.76% and 0.37%.
| Gross Margin | 61.43% |
| Operating Margin | 5.76% |
| Pretax Margin | 0.39% |
| Profit Margin | 0.37% |
| EBITDA Margin | 14.29% |
| EBIT Margin | 5.76% |
| FCF Margin | 15.37% |
Dividends & Yields
MEDXF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.26% |
| Shareholder Yield | -22.26% |
| Earnings Yield | 0.58% |
| FCF Yield | 24.34% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 19, 2018. It was a reverse split with a ratio of 0.0666666.
| Last Split Date | Dec 19, 2018 |
| Split Type | Reverse |
| Split Ratio | 0.0666666 |
Scores
MEDXF has an Altman Z-Score of 0.53 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.53 |
| Piotroski F-Score | 7 |